Estimates and predictors of HIV viral non‐suppression in South African adults on antiretroviral treatment
Journal of the International AIDS Society · 2026
DOI: 10.1002/jia2.70076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2026. Verfasst von Haroon Moolla und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: HIV Infections, Viral Load, Heterocyclic Compounds, 3-Ring, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, FIC NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Introduction
Viral suppression estimates are essential for monitoring the performance of HIV programmes. South Africa introduced dolutegravir (DTG)‐based antiretroviral therapy (ART) in 2019. We sought to generate updated estimates of viral suppression in South African adults on ART and investigate predictors of viral non‐suppression.
Methods
This retrospective cohort study used data from seven South African cohorts participating in the International epidemiology Databases to Evaluate AIDS collaboration. Three main analyses were performed using a viral suppression threshold of 1000 HIV RNA copies/ml. In the first analysis, we fitted a logistic regression model using the full data from the study period (2005−2023). Then, in two causal analyses, we used logistic regression with inverse probability weighting to assess the effects of starting ART on DTG‐based regimens (as opposed to starting on non‐DTG‐based ART) and switching to DTG while virally suppressed (compared to remaining on non‐DTG‐based ART). In sensitivity analyses, we reduced the suppression threshold to 400 copies/ml and excluded those with missing baseline CD4+ cell count measurements.
Results
There were 380,720 participants contributing 2,090,912 person‐years of observation. Most participants were female (64.7%), and the median age at ART initiation was 35.0 years (interquartile range 28.9−42.3). Viral suppression increased over time, reaching 95.9% in 2023. Twenty‐one percent of participants either started ART on DTG‐based regimens (7.1%) or switched to DTG‐based regimens from a virally suppressed state (14.0%). DTG‐based ART was protective against viral non‐suppression in both causal models, with adjusted odds ratios of 0.54 (95% confidence interval [CI] 0.48−0.61) and 0.36 (95% CI 0.32−0.39) for those initiating ART on DTG and those switching to DTG, respectively. A history of ART interruption was strongly associated with viral non‐suppression, with adjusted odds ratios ranging from 2.49 to 4.55. The odds of non‐suppression decreased with increasing age, increasing duration on ART and increasing baseline CD4+ cell count. Results were consistent across sensitivity analyses.
Conclusions
DTG‐based regimens improve viral suppression among both ART‐naïve individuals and those transitioning while suppressed. ART interruptions pose a risk to the sustained success of ART programmes and may further impede efforts to recover from the impacts of recent funding cuts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, Cape Town, South Africa.
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Division of Infectious Diseases, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
- Departments of Epidemiology and Global Health, Boston University School of Public Health, Boston University, Boston, Massachusetts, USA.
- Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Desmond Tutu Health Foundation, Cape Town, South Africa.
Förderung
- NHLBI NIH HHS
- FIC NIH HHS
- NIAAA NIH HHS
- the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases
- NCI NIH HHS
- NIDDK NIH HHS
- NIDA NIH HHS
- NIAID NIH HHS
Zitieren
APA
Moolla, H., Kassanjee, R., Euvrard, J., Maartens, G., Prozesky, H. W., Fox, M. P., Orrell, C., Fatti, G., Tanser, F., Wandeler, G., Davies, M. A., Waal, R., Nyakato, P., Johnson, L. F., & International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA‐SA) Collaboration (2026). Estimates and predictors of HIV viral non‐suppression in South African adults on antiretroviral treatment. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70076
Vancouver
Moolla H, Kassanjee R, Euvrard J, Maartens G, Prozesky HW, Fox MP, et al. Estimates and predictors of HIV viral non‐suppression in South African adults on antiretroviral treatment. Journal of the International AIDS Society. 2026. doi:10.1002/jia2.70076
BibTeX
@article{Moolla2026,
author = {Moolla, Haroon and Kassanjee, Reshma and Euvrard, Jonathan and Maartens, Gary and Prozesky, Hans W and Fox, Matthew P and Orrell, Catherine and Fatti, Geoffrey and Tanser, Frank and Wandeler, Gilles and Davies, Mary-Ann and Waal, Renee de and Nyakato, Patience and Johnson, Leigh F and International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA‐SA) Collaboration, International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA‐SA) Collaboration},
title = {Estimates and predictors of HIV viral non‐suppression in South African adults on antiretroviral treatment},
journal = {Journal of the International AIDS Society},
year = {2026},
doi = {10.1002/jia2.70076}
}
EUVIMED